Company Overview of BioMarin Nederland B.V.
BioMarin Nederland B.V., a biotechnology company, engages in the discovery and development of ribonucleic acid-modulating therapeutics for the treatment of genetic disorders. Its products focus on the treatment of neuromuscular and neurodegenerative disorders, including duchenne muscular dystrophy (DMD), myotonic dystrophy, and huntington’s diseases. The company develops drisapersen, which is in Phase III studies to restore dystrophin expression and enhancing muscle condition; PRO044 that is in Phase I/II studies to address a separate sub-population of DMD patients; and PRO045, PRO053, PRO052, and PRO055 to address other distinct sub-populations of DMD patients. It also develops PRO135 that ...
J.H. Oortweg 21
Leiden, 2333 CH
Founded in 1997
Key Executives for BioMarin Nederland B.V.
Co-Founder and Scientific Director
Founder, Chief Development Officer and Member of Scientific & Clinical Advisory Board
Chief Financial Officer and Member of Management Board
Chief Business Officer, Senior Vice President of Business Development and Member of Management Board
Chief Medical Officer, Senior Vice-President of R&D and Member of Management Board
Compensation as of Fiscal Year 2015.
BioMarin Nederland B.V. Key Developments
Davis Polk Wins Motion to Dismiss in Prosensa Holding N.V. Securities Litigation
May 8 15
On May 5, 2015, Davis Polk achieved a total victory in a securities litigation filed against its clients Prosensa Holding N.V. and several of Prosensa's individual officers and directors. The case captioned Singh v. Schikan, Case No. 14 Civ. 5450, and filed in the U.S. District Court for the Southern District of New York related to Prosensa's June 2013 initial public offering. Plaintiffs, claiming violations of Sections 11 and 15 of the Securities Exchange Act of 1933, alleged that Prosensa's Registration Statement omitted material facts concerning Prosensa's then-ongoing Phase III trial of its lead drug, drisapersen. Davis Polk filed a motion to dismiss, arguing that Prosensa was under no duty to disclose inferences conclusions, or characterizations concerning the Phase III trial or to predict its outcome or otherwise offer opinions on its likely success. The motion to dismiss further argued that, because of the disclosed relationship between Prosensa and its former licensing partner GlaxoSmithKline, certain of the alleged omitted facts were not within Prosensa s knowledge and it therefore had no duty to disclose them. Judge Naomi Reice Buchwald of the Southern District of New York agreed with Prosensa s arguments and dismissed the case outright, denying plaintiffs request for leave to amend their complaint. In doing so, the court rejected each of plaintiffs claims, holding that plaintiffs had failed to allege any actionable material omissions. Judge Buchwald found that defendants were not required to predict negative results and that plaintiffs failed to allege that Prosensa knew or could have known that the Demand III study would not meet its primary endpoint. The court further found that Prosensa had no duty to disclose opinions concerning the then-unknown outcome of the trial, where, as here, all necessary facts were disclosed.
BioMarin Nederland B.V. Auditor Raises 'Going Concern' Doubt
Apr 30 15
BioMarin Nederland B.V. filed its 20-F on Apr 30, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Prosensa Therapeutics B.V. has Changed its Name to BioMarin Nederland B.V
Apr 28 15
Prosensa Therapeutics B.V. changed its name to BioMarin Nederland B.V.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 24, 2014